Page last updated: 2024-11-01

nortriptyline and Fatty Liver

nortriptyline has been researched along with Fatty Liver in 1 studies

Nortriptyline: A metabolite of AMITRIPTYLINE that is also used as an antidepressive agent. Nortriptyline is used in major depression, dysthymia, and atypical depressions.
nortriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(methylamino)propylidene group at position 5. It is an active metabolite of amitriptyline.

Fatty Liver: Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Chu, Q2
An, J2
Liu, P2
Song, Y2
Zhai, X2
Yang, R2
Niu, J2
Yang, C2
Li, B2

Other Studies

1 other study available for nortriptyline and Fatty Liver

ArticleYear
Repurposing a tricyclic antidepressant in tumor and metabolism disease treatment through fatty acid uptake inhibition.
    The Journal of experimental medicine, 2023, 03-06, Volume: 220, Issue:3

    Topics: Animals; Antidepressive Agents, Tricyclic; Drug Repositioning; Fatty Acids; Fatty Liver; Liver; Meta

2023
Repurposing a tricyclic antidepressant in tumor and metabolism disease treatment through fatty acid uptake inhibition.
    The Journal of experimental medicine, 2023, 03-06, Volume: 220, Issue:3

    Topics: Animals; Antidepressive Agents, Tricyclic; Drug Repositioning; Fatty Acids; Fatty Liver; Liver; Meta

2023
Repurposing a tricyclic antidepressant in tumor and metabolism disease treatment through fatty acid uptake inhibition.
    The Journal of experimental medicine, 2023, 03-06, Volume: 220, Issue:3

    Topics: Animals; Antidepressive Agents, Tricyclic; Drug Repositioning; Fatty Acids; Fatty Liver; Liver; Meta

2023
Repurposing a tricyclic antidepressant in tumor and metabolism disease treatment through fatty acid uptake inhibition.
    The Journal of experimental medicine, 2023, 03-06, Volume: 220, Issue:3

    Topics: Animals; Antidepressive Agents, Tricyclic; Drug Repositioning; Fatty Acids; Fatty Liver; Liver; Meta

2023